Scientific and Medical Equipment House (4014.SR) — Income statement
Revenue, gross profit, operating income, net income, and EPS for Scientific and Medical Equipment House — annual and quarterly.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 877↓0.1% | 877↑9.8% | 799↑12.0% | 714↑2.1% | 699 | |
| Cost of Revenue | 755↓9.9% | 838↑25.8% | 666↑19.2% | 559↑2.3% | 546 | |
| Gross Profit | 122↑211.0% | 39↓70.5% | 133↓14.1% | 155↑1.2% | 153 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 16↓13.0% | 19↑4.0% | 18↓73.5% | 68↑23.8% | 55 | |
| Selling & Marketing Expenses | 10↑24.9% | 8↑35.1% | 6↓43.7% | 10↓1.9% | 10 | |
| SG&A Expenses | 26↓1.8% | 26↑11.6% | 24↓69.6% | 78↑19.7% | 65 | |
| Other Expenses | 56↑27.6% | 44↑2322.9% | -2↓105.0% | 39↑782.7% | 4 | |
| Operating Expenses | 82↑16.6% | 71↑9.6% | 64↓45.1% | 117↑68.7% | 70 | |
| Total Costs & Expenses | 837↓0.1% | 838↑14.7% | 731↑8.0% | 676↑9.8% | 616 | |
| Operating Results | ||||||
| Operating Income | 40↑2.5% | 39↓42.8% | 69↑35.5% | 51↓48.7% | 99 | |
| Depreciation & Amortization | 17↑55.3% | 11↓50.6% | 23↑67.7% | 14↑5.4% | 13 | |
| EBITDA | 58↑14.2% | 50↓49.9% | 101↑65.2% | 61↓45.4% | 112 | |
| EBIT | 40↑2.5% | 39↓50.0% | 78↑65.3% | 47↓52.0% | 99 | |
| Interest & Other Income | ||||||
| Net Interest Income | -15↑40.2% | -25↓0.3% | -25↓20.0% | -21↓50.7% | -14 | |
| Interest Income | 0.00 | 0.00↓100.0% | 3↓87.1% | 20 | 0.00 | |
| Interest Expense | 15↓40.2% | 25↓8.8% | 28↑32.6% | 21↑50.1% | 14 | |
| Non-Operating Income | 0.00 | 0.00↑100.0% | -10↓406.6% | 3 | 0.00 | |
| Other Income / Expenses | -0.06↑99.4% | -12↑25.8% | -16↑31.5% | -23↓64.1% | -14 | |
| Income Before Tax | 40↑2.3% | 39↓25.9% | 53↑90.9% | 28↓67.3% | 85 | |
| Income Tax Expense | 14↓4.8% | 15↓3.3% | 15↑25.0% | 12↑49.9% | 8 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 26↓16.1% | 31↓17.4% | 38↑142.1% | 16↓79.7% | 77 | |
| Net Income from Discontinued Operations | 0.00↑100.0% | -7 | 0.00 | 0.00 | 0.00 | |
| Net Income | 28↑15.4% | 25↓38.6% | 40↑128.0% | 18↓77.3% | 78 | |
| Bottom-Line Net Income | 28↑15.4% | 25↓38.6% | 40↑128.0% | 18↓77.3% | 78 | |
| EPS (Basic) | 0.95↑9.2% | 0.87↓35.1% | 1.34↑127.1% | 0.59↓77.1% | 2.58 | |
| EPS (Diluted) | 0.95↑9.2% | 0.87↓35.1% | 1.34↑127.1% | 0.59↓84.8% | 3.88 | |
| Weighted Average Shares | 30↑5.7% | 28↓5.7% | 30↑0.0% | 30↑50.0% | 20 | |
| Weighted Average Diluted Shares | 30↑5.7% | 28↓5.7% | 30↑0.0% | 30↑50.0% | 20 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.